TOP TEN perturbations for 28946 (Homo sapiens)

Organism: Homo sapiens
Gene: 28946
Selected probe(set): 237625_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 28946 (237625_s_at) across 5339 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample

Relative Expression (log2-ratio):-6.0396047
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal plasmocytoid dendritic cell sample
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):5.541063
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):5.166691
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.

osteoarthritis study 4 / rheumatoid arthritis study 2

Relative Expression (log2-ratio):-4.6904087
Number of Samples:5 / 6
Experimental osteoarthritis study 4
Synovial tissue biopsy from a swollen knee of patients with osteoarthritis (active disease). Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control rheumatoid arthritis study 2
Synovial tissues from rheumatoid arthritis patients.

microcrystalline arthritis study 1 / rheumatoid arthritis study 2

Relative Expression (log2-ratio):-4.4676895
Number of Samples:4 / 6
Experimental microcrystalline arthritis study 1
Synovial tissue biopsy from a swollen knee of patients with microcristalline arthritis (active disease). The diagnosis of microcrystalline arthritis was based on the identification of urate or calcium pyrophosphate crystals in the synovial fluid. Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control rheumatoid arthritis study 2
Synovial tissues from rheumatoid arthritis patients.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):4.329637
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

seronegative arthritis study 1 / rheumatoid arthritis study 2

Relative Expression (log2-ratio):-4.2616396
Number of Samples:4 / 6
Experimental seronegative arthritis study 1
Synovial tissue biopsy from a swollen knee of patients with seronegative arthritis (active disease). The diagnosis of seronegative arthritis was based on the presence of psoriasis or x-ray evidence of sacro-iliacal joint involvement. Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control rheumatoid arthritis study 2
Synovial tissues from rheumatoid arthritis patients.

multiple sclerosis study 10 (PP-MS) / cerebrospinal fluid cell sample (mixed neuropathologies)

Relative Expression (log2-ratio):4.0235815
Number of Samples:10 / 9
Experimental multiple sclerosis study 10 (PP-MS)
Cerebrospinal fluid (CSF) cell samples from patients with primary progressive multiple sclerosis (PP-MS). Active disease was defined by the presence of any of the following criteria during 6 month prior CSF collection: (1) one or more relapses, (2) change of 0.5 point or greater in EDSS (Expanded Disability Status Score), (3) change in the number and size of lesions visualized by gadolinium-enhanced MRI. Untreated MS patients did not receive any medication for at least 1 year before CSF sample collection.
Control cerebrospinal fluid cell sample (mixed neuropathologies)
Cerebrospinal fluid (CSF) cell samples from patients with different neuropathologies, other than multiple sclerosis.

multiple sclerosis study 3 (relapse) / unaffected CSFC sample

Relative Expression (log2-ratio):3.9067745
Number of Samples:11 / 18
Experimental multiple sclerosis study 3 (relapse)
Cerebrospinal fluid cell (CSFC) samples from patients with diagnosed relapse-remitting Multiple Sclerosis (RR-MS). Samples were taken during relapse initiated no more than two weeks earlier.
Control unaffected CSFC sample
Cerebrospinal fluid cell (CSFC) samples from patients with a non-inflammatory neurological disease (psychosis, vertigo, paresthesia, cervical spinal stenosis, ependymoma, headache, hereditary spastic paresis, migraine, muscle pain, neurasthenia, sensory symptoms, vertebral dissection or dissociative motor disorder). Patients were unaffected of multiple sclerosis.

ulcerative colitis study 5 (baseline; non-responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):3.7391014
Number of Samples:16 / 6
Experimental ulcerative colitis study 5 (baseline; non-responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.